These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9834211)

  • 1. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
    Przepiorka D; Phillips GL; Ratanatharathorn V; Cottler-Fox M; Sehn LH; Antin JH; LeBherz D; Awwad M; Hope J; McClain JB
    Blood; 1998 Dec; 92(11):4066-71. PubMed ID: 9834211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for CD2 antibodies (BTI-322 and its humanized form) in the in vivo elimination of human T lymphocytes infiltrating an allogeneic human skin graft in SCID mice: an Fcgamma receptor-related mechanism involving co-injected human NK cells.
    Snanoudj R; Rouleau M; Bidère N; Carmona S; Baron C; Latinne D; Bazin H; Charpentier B; Senik A
    Transplantation; 2004 Jul; 78(1):50-8. PubMed ID: 15257038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.
    Koenecke C; Shaffer J; Alexander SI; Preffer F; Dombkowski D; Saidman SL; Dey B; McAfee S; Spitzer TR; Sykes M
    Exp Hematol; 2003 Oct; 31(10):911-23. PubMed ID: 14550807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody.
    Sellberg F; Berglund D; Binder C; Hope J; Fontenot J; Griesemer A; Sykes M; Sachs DH; Berglund E
    Scand J Immunol; 2020 Jan; 91(1):e12839. PubMed ID: 31630416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
    Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R
    Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
    van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
    Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.
    Pruett TL; McGory RW; Wright FH; Pescovitz MD; Yang H; McClain JB
    Transplant Proc; 2009 Nov; 41(9):3655-61. PubMed ID: 19917362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.
    Racadot E; Milpied N; Bordigoni P; Cahn JY; Plouvier E; Lioure B; Lutz P; Wijdenes J; Herve P
    Bone Marrow Transplant; 1995 May; 15(5):669-77. PubMed ID: 7670394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation.
    Lerut J; Van Thuyne V; Mathijs J; Lemaire J; Talpe S; Roggen F; Ciccarelli O; Zuckermann M; Goffette P; Hope J; Gianello P; Bazin H; Cornet A; Rahier J; Latinne D
    Transplantation; 2005 Nov; 80(9):1186-93. PubMed ID: 16314784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.
    Mollee P; Morton AJ; Irving I; Durrant S
    Br J Haematol; 2001 Apr; 113(1):217-23. PubMed ID: 11328304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.
    Fay JW; Wingard JR; Antin JH; Collins RH; Piñeiro LA; Blazar BR; Saral R; Bierer BE; Przepiorka D; Fitzsimmons WE; Maher RM; Weisdorf DJ
    Blood; 1996 Apr; 87(8):3514-9. PubMed ID: 8605372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.
    Nizet Y; Chentoufi AA; de la Parra B; Lewalle P; Rouas R; Cornet A; Besse T; Mourad M; Malaise J; Squifflet JP; Bazin H; Latinne D
    Transplantation; 2000 Apr; 69(7):1420-8. PubMed ID: 10798765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
    Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
    Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.